MAMMÔ 2026 Day 1 Highlights: From Early Detection and Precision Diagnostics to Treatment De-escalation and Global Breast Cancer Care
FDA Approved Atezolizumab Plus Chemotherapy for Stage III dMMR Colon Cancer
Who Shaped Oncology in the First Half of 2026: Breaking Down Approvals by Indications
The Cancer Elimination Collaboration Welcomed Ophira Ginsburg and Dorothy Keefe to the University of Sydney
Emanuela Palmerini: Connecting, Learning and Advancing Oncology at OncoDaily Grand Rounds in Madrid
Enrique Grande: Exploring Long-Term Outcomes and Predictive Biomarkers of Pembrolizumab in Advanced Renal Cell Carcinoma
Armenia Grants World's First Marketing Authorizations for BOT+BAL in MSS mCRC
Bogda Koczwara Named Candidate for UICC Board of Directors 2026–2028
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
